Potential T regulatory cell therapy in transplantation: How far have we come and how far can we go?

Transplant International

Volumn 23, Issue 8, 2010, Pages 761-770

  Battaglia, Manuela ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

regulatory T cells; tolerance; transplantation

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CYCLOSPORIN A; DACLIZUMAB; INOSINATE DEHYDROGENASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RABBIT ANTISERUM; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT;

ALLOIMMUNITY; ALLOTRANSPLANTATION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL THERAPY; CHRONIC GRAFT REJECTION; CYTOKINE PRODUCTION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG EFFECTS; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 77954485583     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01127.x     Document Type: Review

References (58)

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008 133 : 775. (Pubitemid 351707693)
2. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009 30 : 626.
3. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010 11 : 7.
4. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009 30 : 636.
5. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007 13 : 108. (Pubitemid 46341958)
6. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997 389 : 737. (Pubitemid 27458961)
7. Haringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J Exp Med 2009 206 : 1009.
8. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006 212 : 28. (Pubitemid 44116698)
9. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity 2001 14 : 407.
10. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008 358 : 362. (Pubitemid 351159235)
11. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008 358 : 353. (Pubitemid 351159234)
12. Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008 358 : 369. (Pubitemid 351159236)
13. Long E, Wood KJ. Regulatory T cells in transplantation: transferring mouse studies to the clinic. Transplantation 2009 88 : 1050.
14. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008 38 : 925.
15. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007 37 : 129. (Pubitemid 46128793)
16. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009 106 : 13439.
17. Stockis J, Colau D, Coulie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009 39 : 3315.
18. Battaglia M, Roncarolo MG. The Tregs' world according to GARP. Eur J Immunol 2009 39 : 3296.
19. Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009 69 : 599.
20. Serafini G, Andreani M, Testi M, et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica 2009 94 : 1415.
21. Brown K, Wong W. Diagnostic value of regulatory T cells: a new facet of a much studied cell population. Transplantation 2008 86 : 1485.
22. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007 104 : 15448. (Pubitemid 47502937)
23. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006 24 : 99.
24. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002 196 : 401. (Pubitemid 34875668)
25. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002 196 : 389. (Pubitemid 34875667)
26. Zeller JC, Panoskaltsis-Mortari A, Murphy WJ, et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999 163 : 3684. (Pubitemid 29450890)
27. Trzonkowski P, Bieniaszewska M, Juscinska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127- T regulatory cells. Clin Immunol 2009 133 : 22.
28. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to their clinical application. Semin Immunol 2006 18 : 120. (Pubitemid 43248740)
29. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007 21 : 1387. (Pubitemid 46965279)
30. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+ CD25+ Foxp3+ regulatory T cells. J Am Soc Nephrol 2006 17 : 2844.
31. Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+ CD25highFOXP3+ regulatory T cells in vitro. Blood 2008 111 : 3675.
32. LaCorcia G, Swistak M, Lawendowski C, et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009 87 : 966.
33. Broady R, Yu J, Levings MK. ATG-induced expression of FOXP3 in human CD4+ T cells in vitro is associated with T cell activation and not the induction of FOXP3+ T regulatory cells. Blood 2009 114 : 5003.
34. Sewgobind VD, Kho MM, van der Laan LJ, et al. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 2009 24 : 1635.
35. De Serres SA, Sayegh MH, Najafian N. Immunosuppressive drugs and Tregs: a critical evaluation Clin J Am Soc Nephrol 2009 4 : 1661.
36. Wang Z, Shi B, Jin H, Xiao L, Chen Y, Qian Y. Low-dose of tacrolimus favors the induction of functional CD4(+)CD25(+)FoxP3(+) regulatory T cells in solid-organ transplantation. Int Immunopharmacol 2009 9 : 564.
37. Mittal SK, Sharma RK, Gupta A, Naik S. Increased interleukin-10 production without expansion of CD4+ CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. Transplantation 2009 88 : 435.
38. Niemczyk M, Zegarska J, Pawlowska M, Wyzgal J, Ciszek M, Paczek L. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor. Transpl Immunol 2009 20 : 139.
39. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009 66 : 471.
40. Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+ FOXP3+ regulatory T cells. Transplantation 2009 87 : 1062.
41. Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD25 treatment, a functional CD4+ CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007 7 : 249. (Pubitemid 44952880)
42. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 2005 174 : 5187. (Pubitemid 40593155)
43. van de Linde P, Tysma OM, Medema JP, et al. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Hum Immunol 2006 67 : 264.
44. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009 9 : 324.
45. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003 2 : S169.
46. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006 177 : 8338. (Pubitemid 44893795)
47. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood 2005 105 : 4743.
48. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005 201 : 259.
49. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007 18 : 1007. (Pubitemid 46434518)
50. Segundo DS, Ruiz JC, Izquierdo M, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+ CD25+ FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006 82 : 550. (Pubitemid 44290262)
51. Lange CM, Tran TY, Farnik H, et al. Increased frequency of regulatory T Cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin. Transpl Int 2010 23 : 266.
52. Monti P, Scirpoli M, Maffi P, et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+ CD25+ FOXP3+ regulatory T-cells. Diabetes 2008 57 : 2341.
53. Baker AK, Wang R, Mackman N, Luyendyk JP. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol Immunol 2009 46 : 2249.
54. Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009 9 : 2655.
55. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996 10 : 77.
56. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003 101 : 2886. (Pubitemid 36857658)
57. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001 167 : 1945. (Pubitemid 32747499)
58. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006 108 : 390. (Pubitemid 43990654)